| Followers | 843 |
| Posts | 122806 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Tuesday, July 31, 2007 2:50:26 AM
When Viread is approved for HBV, it will probably get the same black-box warning for HIV co-infection that Hepsera already has:
http://www.fda.gov/cder/foi/label/2006/021449s006lbl.pdf (see paragraph 3 inside the black box).
Viread, in combination with two other HIV drugs, is the standard first-line regimen for HIV and is used in more than half of all patients treated for HIV in the U.S. (Note that Viread is a component of the Truvada and Atripla combination pills.)
Clearly, a patient who takes Viread as monotherapy for an extended period in order to treat HBV increases the likelihood of developing resistance to Viread before it can be used in subsequent therapy for HIV. If this occurs, the patient ends up having to take a less-potent and/or less tolerable HIV cocktail that does not include Viread.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
